Impurities provide no benefit to patients; however, it is pragmatically accepted that complex, multi-stage pharmaceuticals cannot be manufactured without drug substance impurities or that drug products cannot be manufactured and stored without degradation products.
This symposium will explore the role of Mass Spectrometry (MS) in the identification and quantification of the various impurities that can be formed.
This symposium should be of interest to development, production, and academic scientists, as well as contract research organisations (CROs)
This symposium will explore the role of Mass Spectrometry (MS) in the identification and quantification of the various impurities that can be formed.
This symposium should be of interest to development, production, and academic scientists, as well as contract research organisations (CROs)
